Evoke Pharma, Inc. (EVOK) financial statements (2021 and earlier)

Company profile

Business Address 420 STEVENS AVENUE
SOLANA BEACH, CA 92075
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments86589914
Cash and cash equivalents86589914
Receivables0      
Inventory, net of allowances, customer advances and progress billings0      
Inventory0      
Prepaid expense1100011
Deferred costs      0
Other current assets0   0 0
Other undisclosed current assets      (0)
Total current assets:966891015
Noncurrent Assets
Operating lease, right-of-use asset00
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:966891015
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1101011
Employee-related liabilities1111111
Other undisclosed accounts payable and accrued liabilities00(1)0(0)00
Debt 0   00
Due to related parties      0
Other liabilities      0
Other undisclosed current liabilities6111111
Total current liabilities:8222122
Noncurrent Liabilities
Long-term debt and lease obligation5    44
Long-term debt, excluding current maturities5    44
Liabilities, other than long-term debt0     0
Deferred revenue and credits   0
Accounts payable and accrued liabilities0      
Other undisclosed noncurrent liabilities   44 (0)
Total noncurrent liabilities:5  4444
Total liabilities:13226666
Stockholders' equity
Stockholders' equity attributable to parent(3)442439
Common stock0000000
Additional paid in capital96908373635245
Accumulated deficit(99)(86)(79)(71)(59)(48)(36)
Total stockholders' equity:(3)442439
TOTAL LIABILITIES AND EQUITY:966891015

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:0      
Operating expenses(13)(7)(8)(11)(11)(12)(13)
Operating loss:(13)(7)(8)(11)(11)(12)(13)
Nonoperating income (expense)(0)00(1)(0)(0)(0)
Interest and debt expense(0)    (1)(0)
Net loss:(13)(7)(8)(12)(11)(13)(13)
Other undisclosed net income attributable to parent0    10
Net loss available to common stockholders, diluted:(13)(7)(8)(12)(11)(12)(13)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(13)(7)(8)(12)(11)(13)(13)
Comprehensive loss, net of tax, attributable to parent:(13)(7)(8)(12)(11)(13)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: